3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other solid neoplasm
2
Conditions
Breast Neoplasms
52
Carcinoma, Renal Cell
47
Neoplasm Metastasis
24
Neoplasms
18
Kidney Neoplasms
18
Neuroendocrine Tumors
17
Carcinoma, Non-Small-Cell Lung
13
Tuberous Sclerosis
12
Stomach Neoplasms
12
Lymphoma, Mantle-Cell
12
Lymphoma, Large B-Cell, Diffuse
11
Recurrence
10
Prostatic Neoplasms
10
Lymphoma
10
Hodgkin Disease
10
Glioblastoma
10
Colorectal Neoplasms
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Brain Neoplasms
9
Lymphoma, Follicular
8
Lung Neoplasms
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Carcinoma
8
Waldenstrom Macroglobulinemia
7
Triple Negative Breast Neoplasms
7
Sarcoma
7
Multiple Myeloma
7
Lymphoma, B-Cell, Marginal Zone
7
Glioma
7
Central Nervous System Neoplasms
7
Interventions
Gemcitabine
9
Paclitaxel
8
Carboplatin
7
atezolizumab
6
Sunitinib
5
navitoclax
4
Topotecan
4
Irinotecan
4
Docetaxel
4
Bevacizumab
4
pazopanib
3
liposomal doxorubicin
3
cobimetinib
3
Nivolumab
3
Erlotinib Hydrochloride
3
zolbetuximab
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
temsirolimus
2
selicrelumab
2
plocabulin
2
envafolimab
2
darinaparsin
2
brigimadlin
2
adavosertib
2
Tablets
2
Sorafenib
2
Rifampin
2
RG7388
2
Panitumumab
2
NVP-BKM120
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Solid Tumors
×
Everolimus
×
Clear all
NCT01349296
2016-05-20
BARIS
University of Cologne
Phase 1
Completed
18 enrolled
NCT00586443
2014-11-19
BEP
Duke University
Phase 1
Completed
56 enrolled